Lupus myositis with normal creatinine kinase levels following adalimumab use in a rheumatoid arthritis patient;Bir romatoid artrit hastasında adalimumab kullanımının ardından gelişen ve normal kreatinin kinaz seviyelerinin eşlik ettiǧi lupus miyoziti

Turkish Journal of Rheumatology

Volumn 26, Issue 4, 2011, Pages 328-332

  Almoallim, Hani ^a,b   Almasari, Ahlam ^b   Khadawardi, Hadeel ^a  

^a UMM AL QURA UNIVERSITY   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Adalimumab; Anti TNF therapy; Drug induced lupus erythematosus; Lupus myositis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CALCIUM; CREATINE KINASE; HYDROXYCHLOROQUINE; METHOTREXATE; METHYLPREDNISOLONE; NAPROXEN; PARACETAMOL; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; VITAMIN D;

ADULT; ANKLE; ARTHRITIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG INDUCED DISEASE; ELBOW; ELECTROMYOGRAPHY; FEMALE; FEVER; FOLLOW UP; HUMAN; JOINT EFFUSION; KNEE; LEG SWELLING; LEUKOPENIA; LUPUS MYOSITIS; LUPUS VULGARIS; LYMPHOCYTOPENIA; METACARPOPHALANGEAL JOINT; MORNING STIFFNESS; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOSITIS; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PHARYNGITIS; POLYARTHRITIS; POPLITEAL CYST; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SHOULDER; SORE THROAT; TREATMENT OUTCOME; ULTRASOUND; UNDIFFERENTIATED ARTHRITIS; WEIGHT REDUCTION;

EID: 84855575456     PISSN: 13090291     EISSN: 13090283     Source Type: Journal    
DOI: 10.5606/tjr.2011.053     Document Type: Article

References (15)

1. Haraoui B, Keystone E. Musculoskeletal manifestations and autoimmune diseases related to new biologic agents. Curr Opin Rheumatol 2006;18:96-100.
2. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51.
3. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847-61.
4. Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90.
5. De Rycke L, Kruithof E, Van Damme N, Hoffman IE, Van den Bossche N, Van den Bosch F, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015-23.
6. van Rijthoven AW, Bijlsma JW, Canninga-van Dijk M, Derksen RH, van Roon JA. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. Rheumatology (O x ford) 20 0 6;45:1317-9.
7. Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2006;55:982-4.
8. Liozon E, Ouattara B, Loustaud-Ratti V, Vidal E. Severe polymyositis and flare in autoimmunity following treatment with adalimumab in a patient with overlapping features of polyarthritis and scleroderma. Scand J Rheumatol 2007;36:484-6.
9. Brunasso AM, Scocco GL, Massone C. Dermatomyositis during adalimumab therapy for rheumatoid arthritis. J Rheumatol 2010;37:1549-50.
10. Vordenbäumen S, Neuen-Jacob E, Richter J, Schneider M. Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFalpha and rituximab. Clin Rheumatol 2010;29:555-8.
11. De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51.
12. Al-Niaimi F. Adalimumab-induced lupus erythematosus. Eur J Dermatol 2009;19:380.
13. Zella GC, Weinblatt ME, Winter HS. Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease. J Pediatr Gastroenterol Nutr 2009;49:355-8.
14. Vannucchi V, Grazzini M, Pieralli F, Giannotta M, Biagioni C, Nozzoli C. Adalimumab-induced lupus erythematosus with central nervous system involvement in a patient with Crohn's disease. J Gastrointestin Liver Dis 2011;20:201-3.
15. Klein R, Rosenbach M, Kim EJ, Kim B, Werth VP, Dunham J. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch Dermatol 2010;146:780-4.